title: Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.
abstract: We carried out Genechip analysis using prostate cancer and non-malignant tissue to identify specific genes related to prostate cancer. We focused on neuroserpin (PI-12), which has been identified as one of the genes with high expression in prostate cancer. We analyzed the relationship between its expression pattern and clinical characteristics. Prostate cancer and normal prostate tissue were analyzed by Affymetrix GeneChip technology. We carried out real-time quantitative PCR on a total of 102 specimens: 45 of normal prostate, 45 of previously untreated prostate cancer (constituting 45 pairs of samples obtained at radical prostatectomy, with each pair dissected from the same prostate specimen) and 12 of recurrent hormone refractory prostate cancer (HRPC). Results showed that the neuroserpin gene was more highly expressed in prostate cancer than in normal prostate tissue. Neuroserpin expression in untreated prostate cancer was significantly higher than that in normal prostate. In HRPC it was significantly higher than that in untreated prostate cancer and normal prostate. In untreated prostate cancer, neuroserpin expression was significantly higher in high grade tumors such as poorly differentiated adenocarcinoma than in lower grade tumors such as well or moderately differentiated adenocarcinoma. Higher neuroserpin expression was associated with shorter recurrence-free survival after radical prostatectomy, shorter recurrence-free survival in HRPC patients and shorter overall survival in HRPC patients. The neuroserpin gene may be associated with the development, progression and aggressiveness of prostate cancer. Our present data suggests that higher neuroserpin expression may predict an unfavorable outcome after radical prostatectomy or hormone therapy.
authors.affiliation: Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Hasumi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakamura
authors.forename: Shinpei
authors.initials: S
authors.lastname: Sugiura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Osada
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Fujinami
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yao
authors.forename: Kenji
authors.initials: K
authors.lastname: Hamada
authors.forename: Hisafumi
authors.initials: H
authors.lastname: Yamada-Okabe
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Hiroji
authors.initials: H
authors.lastname: Uemura
mesh_terms: D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009479:Neuropeptides / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D015843:Serpins / Q000235:genetics*; D015996:Survival Rate; D015854:Up-Regulation; D000097522:Neuroserpin
chemical_list: D009479:Neuropeptides; D015843:Serpins; D000097522:Neuroserpin